Autolus Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Autolus Therapeutics Plc (AUTL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Autolus Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 117M vs 123,910M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+55.7% annualized vs trailing 12 months), vs accelerating (+2.8%) for its tracked peer group.
- Growth: Autolus Therapeutics Plc generated 118.4% revenue growth year over year in Q2 2026, vs 7.3% for its tracked competitors combined.
- Profitability: Its -85.6% net margin compares with -21.3% for the peer group.
- Scale: Autolus Therapeutics Plc ranks #58 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.1% of industry market cap.
- Peer revenue share: Autolus Therapeutics Plc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.16M compares with $1.25M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AUTL Sales vs. its Competitors, Q2 2026
Autolus Therapeutics Plc reported revenue growth of 118.37 % year on year in Q2 2026, above its competitors' combined revenue growth of 7.34 %.
With a net margin of -85.60 %, Autolus Therapeutics Plc reported lower profitability than its competitors (-21.33 %).
Autolus Therapeutics Plc generated 0.14 % of the combined sales of its peer group, up from 0.07 % a year earlier.
Autolus Therapeutics Plc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Autolus Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Autolus Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Autolus Therapeutics Plc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 118.4% for Autolus Therapeutics Plc. Autolus Therapeutics Plc's share of combined industry revenue moved from 0.06% to 0.10%, a gain of 0.05 percentage points.
Autolus Therapeutics Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Autolus Therapeutics Plc | No | - | - | Yes |
| Competitors combined (37) | ||||
| High-Confidence Competitors (16) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AUTL Stock Performance relative to its Competitors
AUTL Stock Performance relative to High-Confidence Competitors
AUTL Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Century Therapeutics inc | 282.9% | Outperformed |
| 5 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Autolus Therapeutics Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Autolus Therapeutics Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Autolus Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Autolus Therapeutics Plc | 495.06 | 117.39 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Moderna Inc | 78,517.44 | 2,228.00 |
| SUBTOTAL | 1,063,303.20 | 189,336.28 |
Sign in to see all competitors of Autolus Therapeutics Plc.
Sources: Autolus Therapeutics Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Autolus Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Autolus Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis | Named by the company | 85% |
| bluebird bio, Inc. | Named by the company | 85% |
| Amgen Inc. | Named by the company | 85% |
| Gilead Sciences, Inc. | Named by the company | 85% |
| BMS | Named by the company | 85% |
| Kite | Named by the company | 85% |
| Seattle Genetics | Named by the company | 85% |
| Tradeup Acquisition Corp | Named by the company | 85% |
| BioNTech SE | Named by the company | 85% |
| Janssen Biotech Inc. | Named by the company | 85% |
| UCLB | Named by the company | 85% |
| AGC Bio | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Kite Gilead | Named by the company | 85% |
| Tecartus | Named by the company | 85% |
| Legend Biotech Corporation | Named by the company | 85% |
| Adicet Bio Inc | Named by the company | 85% |
| King’s College London | Named by the company | 85% |
| Roche Holding AG | Named by the company | 85% |
| Cabaletta Bio Inc | Named by the company | 85% |
| Kymriah | Named by the company | 85% |
| UCL Business Ltd. | Named by the company | 85% |
| Arcellx Inc | Named by the company | 85% |
| Precigen Inc | Named by the company | 85% |
| Allogene Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Autolus Therapeutics Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Autolus Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Autolus Therapeutics Plc | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Precigen Inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Autolus Therapeutics Plc.
Autolus Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Autolus Therapeutics Plc | 495 | 155,690 | -371,564 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Moderna Inc | 78,517 | 474,043 | -670,426 |
| PEERS TOTAL | 1,062,808 | 1,247,496 | 153,291 |
Sign in to see all peers for Autolus Therapeutics Plc.
Autolus Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Exelixis Inc | United States 91.44 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Autolus Therapeutics Plc.
Autolus Therapeutics Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Autolus Therapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.Autolus Therapeutics Plc ranks #58 of 159 companies by market capitalization in its industry, holding 0.06 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,326, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,463 | 25.80 % |
| 2 | Gilead Sciences Inc | 189,197 | 21.46 % |
| 3 | Moderna Inc | 78,517 | 8.91 % |
| 4 | Argenx Se | 64,197 | 7.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 58 | Autolus Therapeutics Plc | 495 | 0.06 % |
Market cap and industry share for the rest of Autolus Therapeutics Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Autolus Therapeutics Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 53 | Aura Biosciences Inc | 583 | 2.30 % |
| 54 | Allogene Therapeutics Inc | 536 | 35.54 % |
| 55 | Valneva Se | 526 | -37.19 % |
| 56 | Zura Bio Limited | 520 | 87.62 % |
| 57 | Prime Medicine Inc | 1,234 | 12.3% |
| 58 | Autolus Therapeutics Plc | 495 | 21.29 % |
| 59 | Tectonic Therapeutic Inc | 1,234 | 12.3% |
| 60 | Eikon Therapeutics Inc | 1,234 | 12.3% |
| 61 | Kyverna Therapeutics Inc | 1,234 | 12.3% |
| 62 | C4 Therapeutics Inc | 1,234 | 12.3% |
| 63 | Fennec Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Autolus Therapeutics Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Autolus Therapeutics Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 15.66 % | 68.46 % (avg) | -52.8 pp |
| Operating Margin | -210.78 % | industry median | -5.8 pp |
| EBITDA Margin | -227.20 % | -0.94 % (avg) | -226.3 pp |
| Capital Intensity (Capex / Revenue) | - | 6.74 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Autolus Therapeutics Plc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 2.7x | 5.1x | -2.4x |
| Return on Equity | -178.66 % | industry aggregate | -175.23 % |
| Return on Invested Capital | -34.40 % | -6.17 % (avg) | -28.23 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Autolus Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | -44.13 % | -79.83 % | - | - |
| Operating Margin | -11,415.14 % | -20,048.60 % | -101,232.53 % | - | -358.87 % |
| Return on Invested Capital | -40.03 % | -23.90 % | -22.63 % | -17.98 % | -28.23 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Autolus Therapeutics Plc's BCG Growth-Share Matrix
Relative market share (vs Autolus Therapeutics Plc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Autolus Therapeutics Plc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Autolus Therapeutics Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,326 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Autolus Therapeutics Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Autolus Therapeutics Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Autolus Therapeutics Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Autolus Therapeutics Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Autolus Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+55.7% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 5.8 points below the industry median.
- Return on equity 175.2 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (51.40 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Autolus Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Autolus Therapeutics Plc | 1.71 | 5.73 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Sign in to see all peers for Autolus Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Autolus Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Autolus Therapeutics Plc | Q2 2026 | +118.4 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +12.8 % | -46.0 % |
Sign in to see all peers for Autolus Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Autolus Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Autolus Therapeutics Plc | Q2 2026 | -16.3 % | -87.5 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Sign in to see all peers for Autolus Therapeutics Plc.
Autolus Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Autolus Therapeutics Plc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Moderna Inc | - | - | - |
Sign in to see all peers for Autolus Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Autolus Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Autolus Therapeutics Plc | - | 4.22 |
| Novartis Ag | 20.53 | 5.07 |
| Amgen Inc | 25.97 | 5.97 |
| Gilead Sciences Inc | - | 6.21 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Moderna Inc | - | 35.24 |
| PEERS AVERAGE | 46.29 | 5.62 |
Sign in to see all peers for Autolus Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.